Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study

Treatment of patients with inflammatory bowel diseases (IBD; Crohn’s disease (CD), ulcerative colitis (UC) who have a prior history of cancer pose a unique challenge. The impact of Vedolizumab (VDZ) on the risk of new or recurrent cancers in patients with a previous malignancy is unknown. This was a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical gastroenterology and hepatology 2022-01, Vol.20 (1), p.88-95
Hauptverfasser:	Vedamurthy, Amar, Gangasani, Nikitha, Ananthakrishnan, Ashwin N.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized Biologics Cancer Recurrence Colitis, Ulcerative - drug therapy Gastrointestinal Agents Humans IBD Inflammatory Bowel Diseases - chemically induced Inflammatory Bowel Diseases - complications Inflammatory Bowel Diseases - drug therapy Neoplasms - chemically induced Neoplasms - drug therapy Neoplasms - epidemiology Retrospective Studies Tumor Necrosis Factor Inhibitors Tumor Necrosis Factor-alpha
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!